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Abstract
Background—We describe the incidence, risk factors, and outcomes of invasive candidiasis in
infants >1500 g birth weight.
Methods—We conducted a retrospective cohort study of infants >1500 g birth weight discharged
from 305 NICUs in the Pediatrix Medical Group from 2001–2010. Using multivariable logistic
regression, we identified risk factors for invasive candidiasis.
Results—Invasive candidiasis occurred in 330/530,162 (0.06%) infants. These were documented
from positive cultures from ≥1 of these sources: blood (n=323), cerebrospinal fluid (n=6), or urine
from catheterization (n=19). Risk factors included day of life >7 (OR 25.2; 95% CI 14.6–43.3),
vaginal birth (OR 1.6 [1.2–2.3]), exposure to broad-spectrum antibiotics (OR 1.6 [1.1–2.4]),
central venous line (OR 1.8 [1.3–2.6]), and platelet count <50,000/mm3 (OR 3.7 [2.1–6.7]). All
risk factors had poor sensitivities, low positive likelihood ratios, and low positive predictive
values. The combination of broad-spectrum antibiotics and low platelet count had the highest
positive likelihood ratio (46.2), but the sensitivity of this combination was only 4%. Infants with
invasive candidiasis had increased mortality (OR 2.2 [1.3–3.6]).
Conclusions—Invasive candidiasis is uncommon in infants >1500 g birth weight. Infants at
greatest risk are those exposed to broad-spectrum antibiotics and with platelet counts of <50,000/
mm3.
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Invasive candidiasis is an important cause of late-onset sepsis in the neonatal intensive care
unit (NICU) and is associated with up to 40% mortality and increased risk of
neurodevelopmental impairment among survivors.1–6 Extremely low birth weight (ELBW,
<1000 g birth weight) infants are at highest risk, with a cumulative incidence of 7%.7–9
Although risk factors for invasive candidiasis in infants <1500 g birth weight have been well
described,3,10,11 there are only limited data on risk factors in larger infants. Previous
multicenter studies examining risk factors for invasive candidiasis included larger infants
together with ELBW infants; studies that focused on larger infants alone have been
predominantly single-center.12–14
The high morbidity associated with invasive candidiasis has led to the evaluation of
prophylaxis and empirical antifungal treatment in high-risk infants in the NICU. Two
clinical trials involving preterm infants revealed benefits of antifungal prophylaxis,8,9 and an
earlier study showed that empirical antifungal therapy was associated with improved
mortality and morbidity of ELBW infants with invasive candidiasis.7 We sought to describe
the epidemiology and risk factors for invasive candidiasis in infants >1500 g birth weight
using a large, multicenter database to inform the need and approach for antifungal
prophylaxis or empirical antifungal therapy in this population.
METHODS
Population
We identified all infants >1500 g birth weight discharged from Pediatrix Medical Group
NICUs between 2001 and 2010. During our study period, the Pediatrix Medical Group
included 305 centers representing both academic and community hospitals in the United
States. We included all blood, urine (obtained by in-and-out catheterization) and
cerebrospinal fluid (CSF) cultures obtained between day of life (DOL) 1 and 120. The data
were obtained from an administrative database that prospectively captures information from
daily progress notes using a computer-assisted tool. Information that was collected included
maternal history, infant demographics, medications, laboratory results, culture results,
diagnoses, and respiratory support. Evaluations for infection were performed using standard-
of-care practices at each NICU. Decisions with regard to obtaining cultures and initiating
therapies were site- and physician-dependent.
Definitions
We defined invasive candidiasis as a positive culture with Candida spp. from blood, urine,
or CSF. We considered all cultures with Candida spp. within a 21-day period as a single
episode of invasive candidiasis and retained the first positive cultures in the dataset for
analysis. We selected pertinent baseline underlying conditions based on prior published
research in neonatal candidiasis from single-center studies in term infants and multicenter
studies in preterm infants: necrotizing enterocolitis (NEC), gastrochisis, omphalocele,
intestinal atresia, Hirschprung’s disease, intestinal perforation, congenital diaphragmatic
hernia (CDH), and congenital heart disease.12,13 We only included NEC treated medically or
surgically and excluded suspected NEC. For congenital heart disease, we included
atrioventricular septal defects, valvular pathologies, obstructive lesions, cyanotic heart
conditions, and single ventricular lesions; we excluded patent ductus arteriosus, atrial septal
defects/patent foramen ovale, and ventricular septal defects from this category. We defined
broad-spectrum antibiotic exposure as treatment with one of the following antibiotics within
seven days prior to the culture: third-generation cephalosporins, carbapenems, ticarcillin, or
piperacillin.11,15 We defined antifungal prophylaxis as an infant with all of the following:
exposure to an antifungal in the first six days of life, antifungal exposure prior to a positive
culture for Candida spp., and antifungal therapy continued for a minimum of eight days. We
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defined antacid exposure as exposure to any of the following medications within seven days
prior to the culture: cimetidine, famotidine, ranitidine, omeprazole, or pantoprazole. We
defined mechanical ventilation (conventional or high-frequency) and inotropic support as
being present on the day of the culture. We identified the maximum fraction of inspired
oxygen (FiO2) recorded. We defined central line use as the presence of an umbilical
catheter, central venous line, and/or peripherally inserted central line on the day of culture,
and categorized this risk factor into three groups: no central line, central line duration ≤7
days, and central line duration >7 days. We defined platelet counts as the highest platelet
count obtained on the day of culture. If no platelet count was obtained on the day of culture,
we used, in order of preference, the platelet count from the previous day or the platelet count
from the following day. Death was defined as death prior to hospital discharge. For length of
stay, we limited our analysis to survivors transferred out or discharged from the NICU.
Statistical Analysis
We compared continuous and categorical variables using the Student’s t-test and chi-square
test, respectively. The unit of observation for risk factor analysis was the culture. We
performed univariable logistic regression of demographic and known risk factors for
neonatal candidiasis. All risk factors were included as candidate variables in a multivariable
model. Because each patient had multiple culture observations, we clustered our
multivariable model by patient. We used stepwise variable selection with an entry P-value
<0.1 and a P-value <0.15 to remain in the model. We reported sensitivity, specificity, and
likelihood ratios of demographics and postnatal age, as well as known risk factors for
neonatal candidiasis alone and in combination. We then compared mortality and length of
stay between infants with and without invasive candidiasis, adjusting for gestational age and
underlying baseline conditions to account for these important covariates. Statistical
significance was defined as P <0.05 for all tests. We analyzed the data using STATA 12
(College Station, TX). This analysis was approved by the Duke University Institutional
Review Board without the need for written informed consent because the data were
collected without identifiers.
RESULTS
There were 530,162 infants >1500 g birth weight. The mean birth weight was 2751 g (5th,
95th percentile: 1660, 4020), and the mean gestational age was 36 weeks (32, 40). Of these,
411,866 (78%) infants had ≥1 blood, urine, or CSF culture, and 330 infants (0.06%)
developed invasive candidiasis (see Table, Supplemental Digital Content 1, http://
links.lww.com/INF/B371 which shows demographics). These episodes were documented
from positive growth of Candida spp. from 323 blood cultures, six CSF cultures, and 19
urine cultures. Among infants with cultures performed, the mean birth weights of infants
with and without invasive candidiasis were 2377 g (1554, 3776) and 2749 g (1656, 4005),
respectively (P <0.001). The mean gestational ages of infants with and without invasive
candidiasis were 35 weeks (30, 40) and 36 weeks (32, 40), respectively (P <0.001). The
mean age of the first episode of invasive candidiasis was 30 days (1, 90). Among the infants
with invasive candidiasis, 213 (65%) infants had a positive Candida spp. culture within the
first 28 days of life. Antifungal prophylaxis was used in 156 infants (0.03%); 118 infants
(76%) were given fluconazole prophylaxis.
While only 4% (19,379/530,162) of infants >1500 g birth weight had pertinent baseline
underlying conditions (see Table, Supplemental Digital Content 1, http://links.lww.com/
INF/B371), these infants represented 42% (140/330) of the cases of invasive candidiasis.
Among the 122 centers with >2000 total discharges, the incidence of invasive candidiasis
ranged from 0.0 to 4.1 per 1000 infants (Figure 1).
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Risk factors for invasive candidiasis identified on unadjusted analysis were gestational age,
lower birth weight, DOL >7, baseline underlying conditions, mechanical ventilation, central
lines, broad-spectrum antibiotics, antacids, antifungal prophylaxis, and platelet count
<50,000/mm3 (Table 1). Risk factors on adjusted analysis included vaginal birth, DOL >7,
presence of central lines, broad-spectrum antibiotics, antifungal prophylaxis, and platelet
count <50,000/mm3 (Table 1).
The combination of broad-spectrum antibiotics and low platelet count had the highest
positive likelihood ratio (46.2) (see Table, Supplemental Digital Content 2, http://
links.lww.com/INF/B372 which shows estimates of sensitivity, specificity, positive
likelihood ratios, and positive predictive values for predictors of invasive candidiasis).
Exposure to broad-spectrum antibiotics, presence of central lines, and platelet count
<50,000/mm3 had sensitivities of 30%, 36%, and 7%, respectively (see Table, Supplemental
Digital Content 2, http://links.lww.com/INF/B372). Likelihood ratios of individual risk
factors were low. Almost all individual risk factor had positive predictive values (PPV)
<1%. Using combinations of risk factors produced higher PPVs (1–3%), but sensitivities for
these combinations were also low (≤8%).
Outcomes Following Invasive Candidiasis
Of the 278 infants with invasive candidiasis and known mortality outcomes, 18 (7%) died.
This was significantly higher than mortality of infants without invasive candidiasis
(2907/369,892 [0.8%], P <0.001). On multivariable analysis, infants with invasive
candidiasis were more likely to die (odds ratio [OR] = 2.2; 95% confidence interval: 1.3,
3.6) than infants without invasive candidiasis. After excluding infants who died, the mean
length of stay for infants with and without invasive candidiasis were 61 days (7, 166) and 12
days (2, 35), respectively (P <0.001).
DISCUSSION
This report of infants >1500 g birth weight with invasive candidiasis found that infants with
invasive candidiasis had higher odds of the following risk factors: vaginal delivery, DOL >7
days, broad-spectrum antibiotics, antifungal prophylaxis, presence of indwelling central line,
and platelet counts <50,000/mm3. In very low birth weight (<1500 g birth weight) infants,
risk factors for invasive candidiasis include lower gestational age, lower birth weight,
presence of central venous catheter, broad-spectrum antibiotics, duration of mechanical
ventilation, and thrombocytopenia.3,10,15–17 In our study, vaginal birth, DOL >7, exposure
to broad-spectrum antibiotics, presence of a central line, and thrombocytopenia were
significant predictors of invasive candidiasis. Our adjusted ORs for thrombocytopenia and
broad-spectrum antibiotics were similar to those previously described for ELBW infants: the
adjusted OR for thrombocytopenia and broad-spectrum antibiotics in infants ≤1250 g birth
weight was 3.6 (2.8–4.7) and 1.8 (1.3–2.3), respectively.11 Our adjusted OR for presence of
a central line was lower (2.3) compared with infants of all birth weights (OR = 3.9 [1.5 –
12.3]).16 In this previous study, central line days were calculated as all line days in the two
weeks prior to the episode of candidemia. Alternatively, we considered a central line as a
risk factor only if it was present when the culture was drawn, and we analyzed this risk
factor by considering the number of days that the central venous catheter had been in place.
Small case series have identified mechanical ventilation and need for inotropes as risk
factors for invasive candidiasis in term infants.14,16 In our cohort, mechanical ventilation
and use of inotropes were not associated with invasive candidiasis. This is analogous to
findings in premature infant studies: earlier single-center studies reported ventilation and
Lee et al. Page 4













inotropes as risk factors for premature infants and invasive candidiasis, but subsequent
multicenter studies did not report such a strong association.3,11,18 These differences may be
due to differences in definitions used in our study compared with previous studies. We
defined mechanical ventilation as support on the day that cultures were drawn, and we did
not include intubation and mechanical ventilation events prior to the drawing of blood
cultures. We considered inotrope use if present only on days when cultures were drawn.
Previous studies defined these risk factors as being present if infants were ever intubated or
required inotropic support.16 The definition used in the present study was more
representative of the severity of illness of the infant at the time of the culture.
A comorbidity identified by previous studies as a strong risk factor for invasive candidiasis
in infants is gastrointestinal pathology.12,13,19 Gastrointestinal pathologies (NEC,
gastrochisis, omphalocele, intestinal atresia, Hirschprung’s disease, intestinal perforation,
CDH) comprised 32% (104/333) of infants with invasive candidiasis in our cohort. On
multivariable analysis, gastrointestinal diagnoses by themselves were associated with
neonatal candidiasis (OR: 1.5 [1.1–2.2]). The lack of association between cardiovascular
diagnoses and invasive candidiasis was consistent with findings in a previous study where
investigators found no difference in the proportion of infants ≥1000 g birth weight with
cardiovascular diagnoses (22/86 vs. 75/258, P=0.53) and invasive candidiasis.20
Antifungal prophylaxis decreases candidiasis in ELBW infants who are hospitalized at
institutions with a high incidence of invasive candidiasis.8,9 We attempted to identify risk
factors that would place larger infants at higher risk for invasive candidiasis to better target
antifungal prophylaxis. However, sensitivity and PPV of all risk factors were low.
Combining risk factors worsened sensitivities while making only slight improvements in
PPV. Increasing the PPV substantially reduces the absolute number of cultures that meet
criteria for prophylaxis. For example, in the instance where PPV was the highest (3.3% for
the combination of broad-spectrum antibiotics and thrombocytopenia), the proportion of all
cultures that would be included in this category was <1/1000 (see Table, Supplemental
Digital Content 2, http://links.lww.com/INF/B372). Designing a prospective trial of
antifungal prophylaxis in infants >1500 g birth weight will involve recruiting infants at the
highest risk, such as those identified by the combination of risk factors found in our study.
Given the rarity of this combination of risk factors and the low incidence of invasive
candidiasis, a trial of this nature will require a prohibitively large number of NICUs.
Invasive candidiasis increases mortality, length of stay, and medical costs in hospitalized
adults, children, and infants.2,21,22 ELBW infants with invasive candidiasis were twice as
likely to die compared with ELBW infants without invasive candidiasis (OR = 2.2 [1.4–
3.5]); furthermore, between 29% and 57% of infants who survived had significant
neurodevelopmental delays at two years of age.3,20,23 We showed that invasive candidiasis
was associated with 40-day increased length of stay, and infants with invasive candidiasis
were more likely to die (OR = 2.2 [1.3–3.6]). Although the adjusted OR for death was
similar to studies in premature infants, the mortality of infants with invasive candidiasis in
our study (7%) was lower than previously reported in more premature infants (20–
54%).14,19,23,24
Bacterial infections in infants are also associated with increased mortality and morbidity.4,25
Although the incidence of early-onset bacterial sepsis in infants is <1%,26,27 empirical
antibiotics are widely used because of the poor clinical outcomes resulting from the delay in
treatment.28 Similarly, Candida spp. infections are associated with increased mortality and
morbidity.3 Delay in treatment of invasive candidiasis results in higher odds of death or
neurodevelopmental impairment.7 Given that the overall incidence of candidiasis was 0.6
per 1000 infants in our study, infants >1500 g birth weight should not be routinely given
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empirical antifungal therapy except when other risk factors are present (e.g., exposure to
broad-spectrum antibiotics and thrombocytopenia).
Our study design allowed us to capture a relatively large number of infants with invasive
candidiasis from a multicenter NICU cohort, but it has several limitations. Compared with
infants >1500 g birth weight in all levels of care, those who were admitted to the NICU were
more likely to have pulmonary disease, congenital anomalies, and require invasive
procedures.29,30 Our estimate of the incidence of invasive candidiasis would be much lower
if we included all infants >1500 g birth weight regardless of level of care. Our dataset did
not have documentation of perinatal Candida spp. colonization or use of total parenteral
nutrition. We thus were not able to examine these previously reported risk factors.16,31 We
did not have records of ophthalmological assessment for fungal retinitis and solid organ
(e.g., liver) involvement. Records of strains of Candida spp. isolated were not available in
our database, and this has limited our availability to investigate the association between
strains and clinical outcomes. Because we do not have data on indication for drug
prescription, we acknowledge that, within our chosen definition of antifungal prophylaxis,
some of this exposure may have been empirical antifungal therapy rather than antifungal
prophylaxis.
The small number of infants with invasive candidiasis limited our ability to provide a better
estimate of our clinical outcome measures or factors associated with these outcomes (e.g.,
center). As part of a sensitivity analysis, we repeated the adjusted risk factor analysis
accounting for center differences by using a random effect model but did not find significant
differences in the odds ratios. Because the Pediatrix Medical Group manages a large number
of infants, the database is considered to be representative of neonatal care in the United
States and has been queried for information by federal agencies such as the Food and Drug
Administration and the National Institute of Child Health and Human Development.
However, the potential generalizability of our findings to NICUs outside of North America
may be limited given the marked variation in incidence of candidiasis in NICUs worldwide.
Invasive candidiasis is rare in infants >1500 g birth weight. Although we identified several
risk factors for invasive candidiasis, these risk factors are not sufficiently robust to identify
populations that will be feasible for the conduct of definitive trials. Given the low incidence
of invasive candidiasis, we did not identify a population in which prophylaxis would be
indicated. The decision to start empirical antifungal therapy should occur after examining
risk factors in the infant in the context of the baseline incidence of invasive candidiasis for
that particular NICU.
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Invasive candidiasis by site (sites with >2000 total discharges). Site numbers 80–122 did not
have any episodes of invasive candidiasis.
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TABLE 1
Risk Factors for Invasive Candidiasis










Vaginal delivery 1.3 (1.0–1.6) 1.6 (1.2–2.3)
Day of life
0–7 Reference Reference
8–30 53.0 (38.1–73.6) 24.0 (13.9–41.6)
31–60 91.1 (62.9–131.7) 35.3 (18.7–66.9)
>60 79.2 (50.6–123.6) 18.1 (7.4–44.5)
Broad-spectrum antibiotics 14.6 (11.6–18.5) 1.6 (1.1–2.4)
Antacids 14.3 (11.0–18.5) 1.5 (1.0–2.3)
Inotropes 1.0 (0.5–2.0) 0.4 (0.2–0.9)
Antifungal prophylaxis 22.4 (10.5–48.2) 6.0 (1.6–22.8)






Central line duration (days)
0 Reference Reference
≤7 0.7 (0.5–1.0) 2.3 (1.5–3.5)
>7 21.3 (16.6–27.4) 2.3 (1.7–3.1)
Platelets <50,000/mm3 9.3 (5.7–14.9) 3.7 (2.1–6.7)
Baseline underlying conditions 9.2 (7.4–11.4)
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